HLA-G Targeted Extracellular Vesicles with Anticancer Drug Loaded (SOB101)

Exosome is natural nano-sized vesicles secreted by cells and found in all biological fluids with distinct internalization mechanisms, low toxicity, low immunogenicity, and high stability. In pursuit of a greater degree of specificity in drug delivery to tumor sites, a genetically engineered exosome designated as SOB101 has been developed. This exosome is equipped with a targeted molecule, namely anti-human leukocyte antigen G (αHLA-G), and it is also encapsulated with the anthracycline-based chemotherapeutic agent, doxorubicin. The αHLA-G molecule has been deliberately chosen for its ability to target the human leukocyte antigen G (HLA-G) which is known to be an immune checkpoint protein responsible for immune evasion and is highly expressed in tumor cells. In the non-clinical animal testing, results demonstrated that high level of chemo-drug doxorubicin in SOB101 up to 5-10-fold of dosage with anti-tumor pharmacoactivity in vivo observed that neither vital organ injury nor alteration of biochemistry, vital organ function including heart function. This excellent drug design showed that the high-level of efficacy, safety, and no significant adverse effects, offer significant advantages and potential as drug carriers in medical applications, with wide-ranging prospects in the future; furthermore, awarded 2022 National Innovation Award by Institute of Biotechnology and Medicine Industry (IBMI) and International Innovation Award (IIA) by the Asian Chamber of Commerce. China Medical University Hospital have collaborated with Shine-On Biomedical with a comprehensive intellectual property portfolio creation including proprietary manufacturing, purification, and preservation methods, as well as a clinical translation platform establishment, our EV novel therapeutics, SOB101, plans to submit a IND Phase I/IIA to the USA FDA in 2024. The future vision is to achieve superior therapeutic efficacy and higher safety compared to existing drug formulations, benefiting cancer patients.

Main Product

HLA-G Targeted Extracellular Vesicles with Anticancer Drug Loaded (SOB101)

Product Introduction

1. Leading Tech in Asia: The unique anti-human leukocyte antigen G (HLA-G) targeting antibody owns high binding affinity to tumor immune-antigen.

2. Chemo-drug encapsulated in HLA-G EVs could significantly reduce the chemo-drug dosage, side effects, and dramatically increase the safety which is neither vital organ injury nor alteration of biochemistry, vital organ function including heart function.

Achievement1

1. Biodistribution: SOB101 precisely navigate to the HLA-G high expression tumor cites.

2. In vivo results: SOB 101 shows the ability to inhibit tumor growth, the efficacy is superior to the unencapsulated drugs and the liposomal drugs.

Achievement2

Certification/Award

• 2022 National Innovation Award by Institute of Biotechnology and Medicine Industry (IBMI)

• 2022 International Innovation Award (IIA) by the Asian Chamber of Commerce.

Contact Information

Unit/Telephone (including extension)/E-Mail

Research & Development Center for x-Dimensional Extracellular Vesicles, R&D Center for xEVs /04-22053366#3725/evinchen@gmail.com